Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0WXUWV)
| ADC Name |
MBRC-101
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
MBRC-101
Click to Show/Hide
|
|||||
| Organization |
MBrace (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-EphA5 mAb
|
Antibody Info | ||||
| Antigen Name |
Ephrin type-A receptor 5 (EPHA5)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
ThioBridge bis-sulfone Val-Cit linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Oesophageal cancer |
1 Trials
|
|||||
| Gastric cancer |
1 Trials
|
|||||
| Pancreatic cancer |
1 Trials
|
|||||
| Liver cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Skin cancer |
1 Trials
|
|||||
| Breast cancer |
1 Trials
|
|||||
| Ovarian cancer |
1 Trials
|
|||||
| Cervical cancer |
1 Trials
|
|||||
| Head and neck cancer |
1 Trials
|